BioNTech completes acquisition of Neon Therapeutics


Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases

BioNTech has announced the closing of the Neon Therapeutics acquisition through an all-stock transaction.

The merger agreement was first announced on 16 January 2020.

The new subsidiary, based in Cambridge (MA, US), will operate under the name of BioNTech US Inc. and serve as BioNTech’s US headquarters.

Sign up for your free email newsletter

As of May 7 2020, Neon’s common stock will no longer be available for trading.